QPS: THE GLOBAL LINK FOR YOUR NEXT ROUND OF PULMONARY AND RESPIRATORY TRIALS

CURRENT CHALLENGES
Without clinical research we couldnt possibly understand the risk factors for developing pulmonary/respiratory disease. We wouldnt know which new therapies might be benecial. We wouldnt know which current therapies might be harmful. But recruitment of patients for randomized clinical trials is often dicult. And because respiratory treatments often have relatively small eects, many randomized controlled trials call for large sample sizes. Enrolling the hundreds or even thousands of patients required is impossible at a single trial site; it demands large networks of clinical investigators working together.

THE GLOBAL FOOTPRINT OF COPD AND ASTHMA

Worldwide:
According to the World Health Organization in 2004, 64 million people worldwide have COPD. The primary cause of COPD is tobacco smoke (through use or second-hand). Almost 90% of COPD deaths occur in low- and middle-income countries. Between 100 and 150 million people around the globe suer from asthma.

Europe:
COPD is the leading cause of lost work days. Asthma has doubled in Western Europe in the past ten years.

WHY CHOOSE QPS TO CONDUCT YOUR PULMONARY AND RESPIRATORY TRIALS?

QPS benets from extensive experience, having conducted over 35 Phase I - IV pulmonary and respiratory studies. This experience covers a range of indications including, but not limited to, COPD, Asthma, ILD and Smoking Cessation. Our well-trained sta work together to produce high-quality studies. QPS has a strong history of supporting clinical research for new pulmonary and respiratory medications in Asia, Europe and the United States. We have the experience to take your compound from the initial planning process, to the collection of clinical evidence, to registration. Our experience can reduce your time-to-market and minimize your costs. QPS will plan your clinical study from start to nish, putting the right team and protocol in place to ensure your trial runs smoothly.

India:
Half a million people die every year due to COPD. Approximately 30 million people have COPD. There are about 15-20 million people living with Asthma.

Taiwan:
COPD was ranked as the sixth cause of death in 2002. The prevalence of asthma symptoms has increased almost vefold in a 20 year period.

QPS FOR YOUR NEXT PULMONARY OR RESPIRATORY TRIAL

Whether you need clinical trials of small molecules, biologics, immunotherapies or other medications, QPS has the experience and resources to handle your trials and get your product to market. Should you want to discuss your questions in more detail with one of our experts, please contact us directly at: info@qps.com

STUDY PARTICIPANTS
Finding the right study patients is crucial for the success of your pulmonary and respiratory trials. QPS has a worldwide database of clinical investigators to ensure high patient enrollment rates conforming to strict selection criteria. The incidence of respiratory disease is so widespread that we can recruit patients with pulmonary or respiratory conditions in a number of dierent countries.

References:
1 2 3 4 5 6 http://www.who.int/mediacentre/factsheets/fs315/en/ http://www.who.int/mediacentre/factsheets/fs206/en/ http://www.european-lung-foundation.org/63-european-lungfoundation-elf-burden-in-europe.htm http://www.japi.org/february_2012_special_issue_copd/01_ed itorial_india_needs_a.pdf Kuo, L, Yang, P, Kuo, S Trends in the Mortality of Chronic Obstructive Pulmonary Disease in Taiwan 19812002. J Formos Med Assoc 2005;104,89-93 http://www.ginasthma.org/pdf/GINABurdenReport.pdf

EXPERIENCED INVESTIGATORS
QPS has developed close relationships with the investigators who conduct your clinical trials. These relationships are the foundation for ensuring quality studies are performed. We take pride in our ability to leverage the skills of the worlds most experienced investigators for every clinical trial we conduct.

Corporate Oce
www.qps.com
Delaware Technology Park, 3 Innovation Way, Suite 240, Newark, DE 19711 Way, Suite Email: info@qps.com TEL: + 1 302 369 5601 F FAX: + 1 302 369 5602 369 5601 2012 QPS Holdings. All Rights Reserved